US 9,428,508 B2Granted

2,4-diamino-6,7-dihydro-5H-pyrrolo[2,3]pyrimidine derivatives as FAK/Pyk2 inhibitors

AssigneeCentaurus Biopharma Co., Ltd.

InventorsDengming Xiao, Liang Cheng, Xijie Liu, Yuandong Hu, Xinhe Xu, Zhihua Liu, Lipeng Zhang, Wei Wu, Shulong Wang, Yu Shen, Gen Li, Yin Wang, Sheng Zhao, Chonglong Li, Jia Tang, Honghao Yu

Life of this patent

Estimating the term…

patentgrep

Loading patent…

Abstract

The invention relates to a novel class of 2,4-diamino-6,7-dihydro-5H-pyrrolo[2,3]pyrimidine derivatives as a FAK and/or Pyk2 inhibitor, to a process for their preparation, and to a composition thereof, as well as to use of the compounds for the inhibiting FAK and/or Pyk2 and method for the treatment of a FAK and/or Pyk2 mediated disorder or disease.

Claims3

Dependent claims

A compound selected from:

or a pharmaceutically acceptable salt, solvate, or tautomer thereof.

Dependencies are inferred from the claim text.

Facts

Application: 13/978,475Filed 7 Jan 2012 · us provisional application
Priority: CN 2011 1 00027767 Jan 2011
Published: US 2013/0281438 A124 Oct 2013
Granted: 30 Aug 2016
Term ends: Not estimatedThe source records don’t support an estimate.

Classification20 codes

C07D 487/04
In which the condensed system contains two hetero rings: ortho-condensed systems
A61K 31/4523
Non condensed piperidines, e.g. piperocaine: containing further heterocyclic ring systems
A61K 31/519
Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim: ortho- or peri-condensed with heterocyclic rings
A61K 31/5377
1,4-Oxazines, e.g. morpholine: not condensed and containing further heterocyclic rings, e.g. timolol